- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03138980
Mobile Self-Management of Irritable Bowel Syndrome for Adolescents
Mobile Self-Management of Irritable Bowel Syndrome for Adolescents: Pilot Study
The objective of the proposed research is to conduct user testing of a mobile-based self-management support intervention for adolescents and young adults with Irritable Bowel Syndrome (IBS), a chronic digestive condition. The application (app; BodiMojo Buddy) uses a virtual coach that can serve to increase patient engagement through interactive skill-building, self-care, and mindfulness-based cognitive behavioral activities. If the BodiMojo Buddy mobile app is successful, it will have a significant public health impact by providing a mobile resource to the 10-15% of the US population who suffer from IBS and potentially improving health outcomes and reducing significant costs to the US healthcare system.
Study participation involves participants downloading and using the app for 30 days. During the 30 days, participants will interact with the app by inputting their current mood, receiving supportive feedback from the app, reading messages, and doing brief activities (such as relaxation activities, etc.). Before and after the 30 days of user testing, participants will complete a few brief questionnaires about their behavior, how their symptoms affect their life, and how they receive support from others. These questions will take around 20 minutes to complete at each administration.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
California
-
Los Angeles, California, Forente stater, 90064
- UCLA Pediatric Pain Program Research Offices
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age 13-21 years
- For adolescents: Parent-reported physician diagnosis of IBS, using pediatric Rome III diagnostic criteria for functional gastrointestinal disorders. For young adults: self-reported physician diagnosis of IBS using Rome III diagnostic criteria, or meeting criteria for IBS or functional abdominal pain as determined during phone screening.
- Have daily use of an iPhone or iPad that meets the following technical specifications: at least iOS 8; for iPhones, must be iPhone 5 or above.
- Able and willing to give informed assent/consent and comply with study requirements
- Have one caregiver willing and able to participate in the study [only for 13-17 year olds]
Exclusion Criteria:
- Inability to provide informed assent/permission/consent
- Inability to read, speak, and understand English (because the app content/parent guides are written in English, as are the measures being used in the study)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Mobil applikasjon
|
Mobile application focusing on emotional coping skills for teens and young adults with IBS.
Components of the module include: mood recorder and "mood cloud," with supportive feedback given based on mood choice; health behavior change support messages informed by mindfulness and self-compassion; quizzes with tailored feedback; library of meditations; an interactive coping skills advice section; and a link to an optional social support feature.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Ratio of the days during the 30-day intervention period during which participants use the app
Tidsramme: 30 days (from day 1 through day 30 of the 30-day intervention period)
|
Determined by how often adolescents engaged and used certain features.
To be considered feasible, teens must have opened the app on at least two-thirds of the days.
|
30 days (from day 1 through day 30 of the 30-day intervention period)
|
|
Acceptance
Tidsramme: Within 7 days of competing the intervention
|
Determined by participants' responses to acceptance test questions in the following domains: (1) perceived connectedness with the Buddy; (2) relevance of the self-management skill building content; and (3) usefulness of self-management skill-building content for IBS.
Responses will be given on a one to seven-point-scale ranging "terrible" to "excellent."
The intervention will be deemed acceptable if at least 80% of participants rate each question an average of at least "5" ("good") on the 7-point scale.
|
Within 7 days of competing the intervention
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 15-001825
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Irritabel tarm-syndrom
-
Seoul National University HospitalUkjentSunn | Kronisk forstoppelse | Constipated Irritable Bowel Syndrome
-
Hacettepe UniversityFullførtTykktarmskreft | Sykepleie | Koloskopi forberedelse | Boston Bowel Preparation ScaleTyrkia
-
GlaxoSmithKlineHar ikke rekruttert ennå
-
Unravel Biosciences, Inc.RekrutteringPitt Hopkins syndromColombia
-
University of California, Los AngelesBoston Children's Hospital; Duke University; Children's Hospital Medical...RekrutteringBohring-Opitz syndrom | ASXL1 genmutasjon | Shashi-Pena syndrom | ASXL2 genmutasjon | Bainbridge-Ropers syndrom | ASXL3 genmutasjonForente stater
-
Helen Keller Eye Research FoundationFive Lakes Clinical Research Consulting, LLCRekrutteringStickler syndrom type 2 | Stickler syndrom type 1Forente stater
-
University of California, DavisNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.FullførtTidligere behandlet myelodysplastisk syndrom | Myelodysplastisk syndrom | Terapierelatert myelodysplastisk syndrom | Sekundært myelodysplastisk syndrom | Refraktært høyrisiko myelodysplastisk syndromForente stater
-
Hospital Universitario GetafeKarolinska Institutet; Medical University of Lodz; Universidad Politecnica... og andre samarbeidspartnereUkjentSkrøpelig eldre syndrom | Skrøpelighet | Skrøpelighet syndromPolen, Spania, Sverige
-
Shaare Zedek Medical CenterUkjentPremenstruelt syndrom - PMS
-
Assistance Publique - Hôpitaux de ParisRekrutteringIntensivavdelingens syndrom | Pediatrisk postintensiv syndromFrankrike
Kliniske studier på BodiMojo Buddy for IBS
-
VA Office of Research and DevelopmentHar ikke rekruttert ennå
-
Sahlgrenska University Hospital, SwedenFullførtIrritabel tarm-syndromSverige
-
Comenius UniversityNational Institute of Children's Diseases, Slovakia; Scientific Grant Agency...RekrutteringForløpercelle lymfoblastisk leukemi-lymfomSlovakia
-
Sally CHANFullført
-
The University of Texas at ArlingtonUniversity of South Florida; Center for Transportation, Equity, Decisions...FullførtMangel på ressurser | Mangel på mobilitetForente stater
-
University of ArizonaNational Heart, Lung, and Blood Institute (NHLBI)UkjentObstruktiv søvnapnéForente stater
-
SingHealth PolyclinicsHar ikke rekruttert ennåOsteoporose risiko | Osteoporose, postmenopausal
-
University of ConnecticutYale UniversityRekrutteringObjektiv integrert multimodal elektrofysiologisk indeks for kvantifisering av visceral smerte (OIME)MagesmerterForente stater
-
Aboca Spa Societa' AgricolaIQVIA RDS; IQVIA SolutionsFullførtIrritabel tarm-syndromItalia, Tyskland
-
Queen's UniversityUkjentIrritabel tarm-syndrom | Visceral overfølsomhetCanada